Diagnósticos da América (DASA3) Q4 2024 earnings summary

Executive summary

• 2024 marked a transformation with operational excellence, cost reduction, and strategic repositioning, including a joint venture with Amil and the sale of non-core Dasa Empresas for R$255 million.

• Operational improvements led to higher NPS scores, efficiency gains, and improved results, notably in hospitals, despite inflation and regulatory cost pressures.

• Capital structure improved, with a significant reduction in net financial debt and a cash balance double the debts due by end-2025.

• The Amil JV created one of Brazil's largest hospital platforms, with CADE approval in January 2025 and ongoing synergy realization.

• Corporate governance enhancements and policy updates were implemented, including sustainability and social responsibility.

Financial highlights

• Consolidated gross revenue reached R$16.8 billion in 2024, up 8% year-over-year; EBITDA grew 11% to R$2.5 billion, with margin up 0.6 p.p. to 16.1%.

• Adjusted gross profit rose 11% to R$4.5 billion; adjusted EBITDA growth would be 23% excluding non-recurring items.

• Operating cash generation was R$910 million, 143% higher than 2023.

• Investments (CapEx) totaled R$547 million, down 25% year-over-year, prioritizing technology and high-return projects.

• Net result was a loss of R$1.2 billion in 2024, 6% higher than 2023, mainly due to higher financial expenses.

Outlook and guidance

• Management expects further deleveraging and operational improvements, with continued focus on cost efficiency, asset utilization, and extracting synergies from the Amil JV.

• Margin and profitability improvements anticipated from digitization, process optimization, and leaner G&A structures.

• Ongoing plans to enhance working capital, optimize receivables, and maintain investment discipline.

• Sustainable profitability and long-term growth remain key transformation goals.